Company ProfilePremium

Carelabs Co., Ltd.

Company Profile Analysis

Ticker: 263700.KQ주식회사 케어랩스

ESOMAR 23 Corporate BadgeISO Certifications Badge
Carelabs Co., Ltd. - Company showcase

Year Founded & Workforce

2012

123 Employees

Carelabs Co., Ltd. logo

Carelabs Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Carelabs Co., Ltd. Overview

Carelabs is a Seoul-based, KOSDAQ-listed digital health and medical-aesthetics platform group controlled since January 2023 by Wonik Holdings, the holding company of a mid-sized Korean semiconductor and battery-equipment conglomerate. Its economic engine today is Babitalk, a medical-beauty information and review platform that generated about KRW 36.8 bn of revenue and KRW 7.3 bn of operating profit in FY2025 and is being absorbed into the parent in December 2026. Around it sit a shrinking parent-level B2B services business (performance marketing for clinics, hospital CRM software, smart-hospital kiosks, medical recruiting), a profitable pharmacy-software subsidiary (EDB), a structurally loss-making telemedicine and booking app (Goodoc), and early-stage bets on oncology information (Heal-O) and senior care. Consolidated revenue has drifted from KRW 93.9 bn (FY2021) to KRW 81.7 bn (FY2025) with recurring operating losses since FY2022. The equity story rests on Babitalk's inbound medical-tourism opportunity and Korea's December 2026 telemedicine legalisation, offset by governance, scale and liquidity concerns.


Company's own description

In its corporate materials Carelabs presents itself as a healthcare and beauty-care platform company for everyone, providing comprehensive healthcare IT services that include clinic information services, clinic customer-management software and digital-marketing solutions [S1][S3]. Its IR materials and press releases describe a "digital healthcare value chain" connecting patients, medical staff, hospitals and pharmacies through the parent and three subsidiaries (Goodoc, Babitalk, EDB) [S17][S25]. At the March 2026 AGM management framed 2026 as a turnaround year built on entry into senior care, AI-enhanced services and a "One CareLabs" integration concept [S22].

Independent characterisation

Carelabs is best understood as a holding-style portfolio of five distinct businesses with very different economics:

  1. Medical-aesthetics marketplace (Babitalk) — a two-sided platform monetised primarily through advertising and performance fees paid by plastic-surgery, dermatology and aesthetic clinics. It is the only clearly profitable, growing engine (FY2025 revenue KRW 36.8 bn, operating profit KRW 7.3 bn, ~3,300 hospital/doctor network, 10 million cumulative downloads) [S29][S17].

  2. Parent-level B2B services for clinics — performance/digital-marketing agency services, hospital CRM software ("Uno CRM"/Care CRM), smart-hospital solutions (kiosk payment, certificate issuance, queue management, RFID, QR), and the Medijob/Yobosarang recruiting platforms [S3][S25]. Parent-only revenue fell from KRW 41.0 bn (FY2024) to KRW 33.8 bn (FY2025) and a further 36.2% YoY in Q1 2026 [S1][S12].

  3. Pharmacy software (EDB, 51% owned) — QR-code prescription-security systems and pharmacy claims software; Q1 2026 revenue KRW 3.5 bn (+24% YoY) with operating profit up 255% [S7][S17].

  4. Consumer healthcare access app (Goodoc, 88.74% owned) — clinic search, booking and walk-in registration, telemedicine and prescription transfer. Revenue collapsed from about KRW 12.1 bn (2021) to KRW 1.0 bn (2024 and 2025); the entity has been in full capital impairment since end-2021 [S7].

  5. New bets — Heal-O oncology-journey platform (launched Aug 2025) and a planned senior-care facility on land acquired in Seoul's Godeok-Gangil district (2025) [S26][S30].

Revenue model mix

Revenue typeMain business linesCharacterisation
Advertising / performance fees from clinicsBabitalk, Goodoc, Heal-O (potential)Platform/marketplace revenue; dominant and highest margin
Agency / service feesParent digital-marketing divisionProject and performance-based services; declining
Software licences / subscriptionsHospital CRM, EDB pharmacy software, smart-hospital solutionsRecurring B2B SaaS-like revenue
Hardware-linked solutionsSmart-hospital kiosks, tabletsEquipment plus service; minor cost of sales
Recruitment feesMedijob, YobosarangJob-posting / matching fees

Exact revenue split by revenue type is not publicly disclosed in sources reviewed. Aggregator data based on Q2 2026 filings put the reported segment mix at roughly 50% healthcare media platforms, 26% solutions and 24% marketing [S5]. Cost of revenue is negligible (KRW 0.17–0.94 bn per quarter in 2025–26) because the company presents most expenses within SG&A [S13].

Value-chain position, customers and end markets

Carelabs sits in the demand-generation and workflow layer between consumers and providers. Paying customers are overwhelmingly B2B: private plastic-surgery and dermatology clinics (Babitalk), primary-care clinics and hospitals (Goodoc, CRM, smart hospital), pharmacies (EDB), and healthcare employers including long-term-care institutions (Medijob, Yobosarang). Consumers use most services free of charge. End markets are Korean medical aesthetics, inbound medical tourism (initially Japan), primary care access and telemedicine, pharmacy IT, healthcare staffing and, prospectively, senior care.

Strategy

Stated strategy themes (2026)

Turnaround in 2026: management told shareholders 2026 should lay the foundation for a turnaround, with responsibility for strengthening the competitiveness and profitability of core businesses [S22].

Senior care entry: entering rehabilitation- and care-centred senior care in response to super-ageing, building synergies with digital-health capabilities [S22].

"One CareLabs": linking data accumulated in Goodoc and Babitalk with AI to connect services across the patient journey (search–selection–experience–management) [S22][S24].

Babitalk as core global business: the October 2026 merger is explicitly intended to simplify decision-making, cut duplicated overhead and concentrate resources on Babitalk's global medical-tourism business, including integrated marketing with the parent's performance-marketing unit, more languages and AI features [S21][S73].

Initiative register (last 24 months)

DateInitiativeTypeTarget / scopeSource
Sep 2024–Feb 2025Sale of Yeoksam-dong property interest to Wonik affiliatesBalance-sheet restructuringAbout KRW 74.5–75.4 bn proceeds[S8][S10]
Jul 2025Yobosarang acquisitionBusiness extensionCare-worker recruiting[S25]
Aug 2025Babitalk Japan web serviceInternational expansionJapanese consumers seeking Korean procedures[S28]
Aug 2025Heal-O launchNew platformCancer patients and caregivers[S26]
Sep–Oct 2025Godeok-Gangil land purchasesSenior-care infrastructurePlanned senior-care building[S30][S31]
Nov 2025KRW 10.0 bn Goodoc recapitalisationSubsidiary supportRestore Goodoc equity[S7]
Mar 2026New business purposes (cosmetics, health foods, etc.)OptionalityNot specified[S23]
Apr 2026Heal-O AI upgradeProductAI answers, nursing-hospital search[S27]
H1 2026Babitalk AI search; Japanese appProductReview-based AI search[S17]
Jul 2026C-level hires (CSO, Goodoc CTO)OrganisationStrategy and AI/data[S24]
Oct 2026Babitalk absorptionRestructuringMerger date 18 Dec 2026[S18]

Sustainability / ESG commitments

None disclosed in sources reviewed.

Financial targets / guidance

No quantitative medium-term targets or formal guidance were identified. Historical note: in 2020 a broker expected record operating profit of KRW 7 bn on KRW 78 bn sales; actual FY2020 operating profit was KRW 6.0 bn [S72][S42].

Products & Services

Healthcare media platforms

Babitalk (바비톡) — medical-beauty platform

  • Description: information, review and booking platform for plastic surgery and non-invasive aesthetic procedures (lifting, fillers, botulinum toxin, lasers, skin boosters) [S4][S28].

  • Scale: 10 million cumulative downloads (2026); network of about 3,300 hospitals and doctors; FY2025 revenue KRW 36.8 bn, operating profit KRW 7.3 bn [S17][S29].

  • Recent capabilities: AI search built on review big data, described by the company as an industry first (2026); Japanese web service (Aug 2025) and Japanese app using AI natural-language translation; Japanese-consultation indicators per clinic and direct links to clinic consultation channels [S17][S28].

  • Customers: aesthetic clinics (payers), consumers in Korea and Japan (users).

  • Pricing: advertising and performance-based fees; specific tariffs not publicly disclosed.

  • Launch: Dec 2012 [S2].

Goodoc (굿닥) — clinic search, booking and telemedicine

  • Description: search, review, booking, walk-in registration, telemedicine (video/voice), and prescription transmission to partner pharmacies via a pharmacy admin tool; uses Health Insurance Review & Assessment Service (HIRA) data for clinic information [S4][S46].

  • Products within Goodoc: consumer app; clinic registration tablets; QR check-in kiosks deployed at large hospitals during COVID-19; AI health Q&A service ("24-hour Health Talk") [S69][S46].

  • Scale data points: 7.5 million cumulative downloads and about 1.5 million average MAU (Oct 2021); MAU up 25% YoY in Q1 2026 (absolute figure not disclosed) [S69][S17].

  • Certifications: ISMS certification for the Goodoc service platform, valid 7 Feb 2024 – 6 Feb 2027 [S46].

  • Monetisation: clinic subscriptions/advertising, kiosk and tablet services, prescription-related fees; revenue only KRW 1.0 bn in FY2025 [S7].

  • Launch: May 2012; spun off July 2020 [S2].

Heal-O (힐오) — oncology journey platform

  • Description: cancer-information platform covering symptoms, diagnosis, treatment and recovery for all cancer types, with eight major cancers (liver/biliary, thyroid, colorectal, gastric, breast, prostate, pancreatic, lung) featured; communities by cancer type and stage; "find a top doctor" search using HIRA data; cancer encyclopedia [S26].

  • April 2026 upgrade: AI paper summaries and doctor-selection guide in the doctor search; separate "clinician answer" and "AI answer" Q&A options; new search for cancer-specialised long-term-care hospitals [S27].

  • App store listing cites information on more than 6,000 doctors [App Store listing referenced in S26 context].

  • Pricing: free to users; monetisation model not publicly disclosed.

  • Launch: 27 Aug 2025 [S26].

Medijob (메디잡) and Yobosarang (요보사랑) — healthcare recruiting

  • Medijob: recruiting platform for doctors, nurses, pharmacists, dental hygienists and other medical staff; acquired as a business in Feb 2019 [S2][S25].

  • Yobosarang: care-worker (요양보호사) matching platform acquired from Korea Senior Research Institute in July 2025, used by about 25,000 care workers and 1,500 care institutions at acquisition; integrated posting with Medijob launched May 2026 [S25].

Solutions

ProductDescriptionCustomersSource
Care CRM / Uno CRMClinic customer-management software combining front-desk workflow, patient management and marketing; configurable by clinic size and specialty; integrates with insurance claims and other applicationsClinics, especially non-reimbursed specialties[S3][S26]
Smart Hospital solutionsKiosk-based unattended payment, certificate issuance, intelligent queueing, waiting-time display, RFID, QR platform, online certificates; includes consultingHospitals[S3]
EDB prescription-security systemQR-code based prescription-security system and pharmacy claims softwarePharmacies, clinics[S4]

Marketing

Digital Marketing Division: performance-marketing agency for clients in the medical sector, using targeting to connect clinics with prospective patients [S3][S59]. The October 2026 Babitalk merger is intended to integrate Babitalk platform advertising with this external performance-marketing offer [S73].

Pipeline / planned offerings

Senior-care facility: building planned on Godeok-Gangil commercial land parcel 1-2 (5,462 m², Gangdong-gu, Seoul), acquired for KRW 75.11 bn; management describes entry into rehabilitation- and care-centred senior care [S30][S22].

Consumer products: March 2026 article amendments added manufacturing (including contract manufacturing) and distribution of foods, health-functional foods, cosmetics, beauty goods, quasi-drugs and sundries [S23]. No product launches identified.

Social-dating business (acquired H2 2018), BNK Lab (merged into parent), BeautySocial Inc. (US), Eunogo Pte. Ltd. (Singapore), Uno Beauty, Approdi, Vital Labs (merged into Goodoc), and e-commerce initiatives from 2019 [S2][S40][S63]. Their current status is not disclosed in sources reviewed.

Financial Narrative

Income statement (consolidated)

Sources: FY2023–FY2025 audited figures [S1]; FY2021–FY2022 [S14][S43][S5]; EPS [S11]; dividend yield nil [S5]. Margins derived. FY2025 net income is KRW 19.51 bn on the company IR page (audited) versus KRW 19.47 bn in the February 2026 preliminary filing [S9]; the audited figure is used.

Gross profit: not meaningful; Carelabs reports expenses by nature, and cost of revenue was only KRW 0.17–0.94 bn per quarter in 2025–26, implying gross margin above 95% [S13].

EBITDA: not publicly disclosed in sources reviewed.

Pre-tax income: not publicly disclosed in sources reviewed.

Diluted EPS: not publicly disclosed in sources reviewed.

Revenue CAGR FY2021–FY2025: -3.4% (derived).

Longer history (context)

Sources: [S40][S41][S42][S43][S1][S14].

Quarterly trajectory (consolidated)

Sources: Q1 2025 [S15]; Q2 2025–Q1 2026 [S13]; Q2 2025 net income [S14]; Q2 2026 revenue and operating income derived from H1 2026 totals (revenue KRW 37.9 bn, operating loss KRW 0.048 bn) [S7]. H1 2026 net loss was roughly KRW 1.5 bn [S6].

Balance sheet

Sources: consolidated and separate totals [S1]; separate line items [S12]. Ratios derived. Consolidated cash, total debt split, goodwill and working capital are not publicly disclosed in sources reviewed. At end-2024 consolidated liabilities were KRW 88.3 bn; the February 2025 receipt of property proceeds allowed repayment of most parent borrowings. Retained earnings stood at about KRW -37.6 bn (accumulated deficit) as of the latest period on one aggregator [S5 context: Chickstock], and at about KRW -45 bn in early 2025 [S8]. The parent's separate cash fell further to KRW 6.5 bn at end-March 2026 while PP&E rose to KRW 27.1 bn, consistent with progress payments on the Godeok land [S12].

Paid-in capital was about KRW 9.8 bn at FY2025 [S64].

Cash flow

Operating cash flow, capex, free cash flow, dividends paid and buybacks are not publicly disclosed in sources reviewed. Qualitatively:

  • No dividends have been paid in the period reviewed [S5].

  • No share-buyback authorisation was identified; treasury shares are about 0.07% of shares [S5].

  • Investing cash flows in FY2025 were dominated by receipt of about KRW 74.5–75.4 bn of property-sale proceeds (KRW 14.9 bn deposit in 2024, KRW 59.6 bn balance in Feb 2025) and by deposits/instalments on the Godeok land [S8][S12].

  • Financing outflows in FY2025 included repayment of parent short-term borrowings (KRW 9.0 bn) and most of the KRW 34.0 bn current portion of long-term debt [S12].

Ratios

ROE, ROA and asset turnover for FY2024–FY2025 derived using average balances [S1]. Separate ROA [S11]. Aggregator TTM ROE was -10.9% in October 2026 [S5]. ROIC, current ratio (consolidated), net debt/EBITDA, interest coverage and cash conversion cycle are not publicly disclosed in sources reviewed; one aggregator reports a current ratio of 222.1% on a separate basis [S66].

Commentary on trends and inflections

Growth stalled after the pandemic peak: Revenue rose from KRW 39.3 bn (FY2017) to KRW 93.9 bn (FY2021), helped by acquisitions and COVID-era telemedicine demand, then declined about 13% to FY2025. Goodoc's revenue collapse (KRW 12.1 bn to 1.0 bn) and the shrinking parent marketing business explain most of the decline; Babitalk grew strongly over the same period [S7][S29].

Losses peaked in FY2023: The operating loss of KRW 11.6 bn in FY2023 narrowed to KRW 2.9 bn in FY2025 through cost cuts; the parent's separate management expenses fell from KRW 31.8 bn (FY2024) to KRW 25.5 bn (FY2025) [S12].

FY2025 profit is non-recurring: The KRW 19.5 bn net profit stems from a KRW 25.9 bn gain on the Yeoksam-dong property sold to Wonik affiliates; the company itself attributed the swing to efficiency gains and non-operating income from the asset transfer [S9][S10].

2026 relapse: H1 2026 revenue fell 20.3% YoY to KRW 37.9 bn and the company slipped back to a small operating loss [S7]. Parent-only revenue fell 36.2% YoY in Q1 2026 (KRW 6.7 bn versus 10.5 bn), indicating the decline is concentrated in parent-level services rather than Babitalk [S12]. Management has not publicly provided a detailed explanation for the Q4 2025 and Q2 2026 revenue drops.

Balance-sheet reset, then re-levering into property: FY2025 liabilities fell 63% to KRW 32.8 bn, but the company committed KRW 75.11 bn to Godeok land parcel 1-2 alone; the payment schedule is not disclosed in sources reviewed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipOwnershipActivity

Wonik Holdings Co., Ltd.

Parent (largest shareholder)

32.73% of Carelabs (planned increase to 33.76%)

Wonik Group holding company

Carelabs Co., Ltd.

Listed company

—

Digital marketing, CRM, smart hospital, Medijob, Yobosarang, Heal-O, senior-care project

Babitalk Co., Ltd.

Subsidiary (to be merged 18 Dec 2026)

100% per merger filing (1,015,239 shares); 98.71% per Sept 2026 press

Medical-beauty platform

Goodoc Co., Ltd.

Subsidiary

88.74% (1,446,545 shares)

Booking, registration, telemedicine

EDB Co., Ltd.

Subsidiary

51%

Pharmacy prescription-security and claims software

Segment (Q2 2026) Overview

Segment (Q2 2026)Contents (analyst mapping)Share of revenue (%)Derived Q2 2026 revenue (KRW Bn)

Healthcare media platform

Babitalk, Goodoc, Heal-O, Medijob/Yobosarang (likely)

508.7

Solutions

EDB pharmacy software, hospital CRM, smart hospital

264.5

Marketing

Parent digital-marketing agency

244.2

Revenue by Segment

MetricFY2021FY2022FY2023FY2024FY2025

Consolidated revenue (KRW Bn)

93.9087.6181.8383.1981.69

Carelabs parent revenue, separate (KRW Bn)

——37.2441.0333.82

Babitalk revenue (KRW Bn)

————36.80

Goodoc revenue (KRW Bn)

12.107.804.501.001.00

EDB, other and eliminations, derived residual (KRW Bn)

————10.07

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

MetricFY2023FY2024FY2025

Babitalk operating profit (KRW Bn)

——7.30

Carelabs parent operating profit, separate (KRW Bn)

-3.98-4.16-5.67

Goodoc net profit (KRW Bn)

—2.80—

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

93.9087.6181.8383.1981.69

Revenue growth YoY (%)

22.5-6.7-6.61.7-1.8

Operating income (KRW Bn)

3.28-6.38-11.60-4.46-2.88

Net income (KRW Bn)

1.24-26.39-23.87-19.6719.51

Basic EPS, attributable (KRW)

73-1,434-1,260-1,045—

Dividend per share (KRW)

00000

Operating margin (%)

3.5-7.3-14.2-5.4-3.5

Net margin (%)

1.3-30.1-29.2-23.623.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

39.3454.3868.3076.6793.9087.6181.8383.1981.69

Operating income (KRW Bn)

6.265.073.626.003.28-6.38-11.60-4.46-2.88

Net income (KRW Bn)

5.133.850.534.501.24-26.39-23.87-19.6719.51

Income Statement (Quarterly)

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue (KRW Bn)

23.0722.5221.1614.9520.5417.36

Operating income (KRW Bn)

0.842.58-0.59-5.710.67-0.72

Net income (KRW Bn)

25.45-0.73————

R&D expense (KRW Bn)

—0.390.400.680.39—

Balance Sheet and Margin Analysis (%)

MetricFY2023FY2024FY2025

Total assets, consolidated (KRW Bn)

162.20143.26107.43

Total liabilities, consolidated (KRW Bn)

87.1388.2832.80

Total equity, consolidated (KRW Bn)

75.0754.9874.63

Liabilities-to-equity, consolidated (%)

116.1160.643.9

Total assets, separate (KRW Bn)

138.87118.1183.96

Total liabilities, separate (KRW Bn)

59.0665.817.72

Cash and equivalents, separate (KRW Bn)

5.914.59.7

Short-term borrowings, separate (KRW Bn)

10.09.00.0

Current portion of long-term debt, separate (KRW Bn)

6.134.01.2

Assets held for sale, separate (KRW Bn)

60.748.70.0

Property, plant and equipment, separate (KRW Bn)

2.710.726.1

Intangible assets, separate (KRW Bn)

5.83.03.3

Investments in subsidiaries/associates, separate (KRW Bn)

33.122.231.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, consolidated (%)

———-30.330.1

ROA, consolidated (%)

———-12.915.6

ROA, separate, per FnGuide (%)

1.50-10.56-17.88-20.39—

Asset turnover, consolidated (x)

———0.540.65

Revenue by Region

RegionFY2023FY2024FY2025

Korea revenue, derived as ~100% of consolidated (KRW Bn)

81.8383.1981.69

Share Price

MetricJun 2020Jan 2023Aug 2025Mar 2026Aug 2026Oct 2026

Share price (KRW)

18,7508,4501,8302,3901,9252,015

Valuation Snapshot

MultipleValueBasis

Market capitalisation

KRW 39.1 bn

KRW 2,015 × ~19.41 M shares [S5][S13]

P/E (FY2025)

~2.0x

Distorted by one-off gain; one aggregator showed 2.02x TTM earlier in 2026 [S58]

P/B

0.59x

[S5]

EV/Sales

not computed

—

Price/Sales (FY2025)

0.48x

KRW 39.1 bn / KRW 81.69 bn

Analyst Conclusions

Management guidance and consensus

No quantitative guidance or consensus forecasts are available. Management's qualitative messages are: 2026 as a turnaround-foundation year; growth from Babitalk (including Japan) and EDB; expansion into senior care; and AI-led product upgrades [S22][S17].

Bull case

  1. Babitalk is undervalued inside the group. A business with KRW 36.8 bn revenue and KRW 7.3 bn operating profit in FY2025, growing past KRW 10 bn per quarter, is worth more on peer-implied multiples than the whole group's ~KRW 39 bn market cap; the merger into the parent makes this value directly attributable to listed shareholders [S29][S17][S18].

  2. Demand tailwind from medical tourism. Foreign patients doubled to 2.01 million in 2025, with dermatology and plastic surgery leading growth; Japanese-language services position Babitalk for Korea's second-largest source market [S50][S28].

  3. Cleaner balance sheet plus sponsor support. Parent liabilities fell to KRW 7.7 bn, and Wonik Holdings and the CEO are buying shares, signalling the group will continue backing the company [S1][S6].

Bear case

  1. Structural decline outside Babitalk. Parent revenue fell 36.2% YoY in Q1 2026 and group revenue fell 20.3% in H1 2026; Goodoc remains in capital impairment despite KRW 20 bn of injections [S12][S7].

  2. Capital allocation risk. Committing KRW 75.11 bn (52.43% of then assets) to land for an unproven senior-care business, while parent cash is single-digit KRW billions, raises funding and return risks [S30][S12].

  3. Competitive and regulatory pressure. Gangnam Unni is larger, more profitable and further ahead in Japan; telemedicine platforms face conduct and advertising restrictions just as Goodoc lags Doctor Now [S52][S53][S49][S54].

Catalysts and monitorables (next 12 months)

  • Q3 2026 results (expected 12 Nov 2026) and explanation of the revenue decline [S57].

  • EGM on 26 Nov 2026 (articles amendment) and completion of the Babitalk merger on 18 Dec 2026 [S20][S18].

  • Telemedicine law implementation (expected late Dec 2026) and Goodoc's response [S48].

  • Disclosure of Godeok land payment schedule, construction financing and senior-care business plan.

  • Babitalk Japan traction metrics (users, partner clinics, revenue).

  • Wonik Holdings' stake changes and any further related-party transactions.

  • Market capitalisation versus the KRW 30 bn KOSDAQ threshold applying from 2027 [S6].

  • FY2026 annual report (March 2027): segment detail, cash-flow statement and impairment testing.

Analyst verdict

Carelabs is a small, controlled holding-style company whose listed value is now largely a claim on one good business. Babitalk is profitable, growing and strategically well placed to capture the extraordinary rise in foreign demand for Korean aesthetic medicine. Its FY2025 operating profit of KRW 7.3 bn compares with a group market capitalisation of roughly KRW 39 bn, and the December 2026 merger removes a layer between Babitalk's cash flows and public shareholders. On that narrow lens the stock screens as deeply undervalued at about 0.6x book and 0.5x sales.

The difficulty is everything around Babitalk. Group revenue has fallen for most of the last four years, the parent's service businesses are contracting sharply, and Goodoc has absorbed capital while its revenue collapsed. FY2025's headline profit came from selling property to sister companies, not from operations, and H1 2026 slipped back into an operating loss. Management has simultaneously committed a sum comparable to half of its then-assets to land for a senior-care venture with no disclosed business plan or funding structure, at a time when parent cash was below KRW 10 bn. Governance also deserves a discount: control sits with a sponsor whose interests extend across the Wonik Group, intra-group transactions have been used to fund the company, and executive leadership has been concentrated in the controlling family.

Overall, the evidence supports a cautious, event-driven stance rather than a fundamental long-term conviction. The investment case improves materially if (1) Babitalk's growth and margins are sustained after the merger and become visible in segment reporting, (2) the Godeok project is financed without straining the parent or diluting shareholders, and (3) losses at Goodoc and the parent are contained. Absent clear progress on these points by the FY2026 annual report, the persistent valuation discount is likely to remain justified. Data gaps (cash flow, segment profits, risk disclosures) should be closed through DART filings before any position is taken.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundAge

Lee Min-kyung (이민경)

CEO and inside director, Carelabs; director of Goodoc, Babitalk, EDB

CSO and director from Jan/Feb 2023; CEO from Jan 2025; re-elected Mar 2026

Fine arts and crafts graduate of a US art university; manager at CMS Lab (medical cosmetics) Feb 2014–Feb 2019; M&A head, Wonik Holdings strategy office Mar 2019–Jan 2023; eldest daughter of Wonik founder-chairman Lee Yong-han

37 (Sep 2026 press)

Jang Young-ju (장영주)

CEO, Goodoc; Carelabs director

Carelabs board from Mar 2025; Goodoc CEO from Nov 2025

—44

Kim Ji-woong (김지웅)

Chief Strategy Officer, Carelabs

Appointed Jul 2026

Formerly Amazon and Toss Bank

—

Lee Won-hee (이원희)

CTO, Goodoc

Appointed Jul 2026

Formerly Coupang and Samsung Electronics

—

Shin Jung-in (신정인)

CEO, Babitalk

Current

——

Oh Se-jin (오세진)

CSO, Babitalk

Current (2025)

——

Kim Ju-sung (김주성)

Outside director, Carelabs

Re-elected Mar 2026

——

Ji Myung-chan (지명찬)

Standing statutory auditor, Carelabs

Re-elected Mar 2026

——

“—” = not publicly disclosed.

Board & Management Changes

DateChange

Nov 2018

Park Kyung-deuk appointed CEO (co-CEO with Kim Dong-soo)

Dec 2019

Park Kyung-deuk becomes sole CEO

Jan 2023

Shin Jong-hyun appointed CEO upon Wonik takeover

Jan 2025

Lee Min-kyung succeeds Shin Jong-hyun as CEO

Nov 2025

Jang Young-ju appointed Goodoc CEO

Mar 2026

Outside-director changes filed; CEO re-elected; audit-committee clause deleted from articles (company uses a standing auditor)

Jul 2026

New CSO (parent) and CTO (Goodoc)

Major Shareholders

HolderSharesStake (%)Note

Wonik Holdings

6,353,44232.73

Average cost about KRW 12,234/share (KRW 77.7 bn total); 200,000-share open-market purchase announced from 7 Sep 2026, which would lift the stake to 33.76%

Lee Min-kyung (CEO)

53,4720.28

Bought on market 8 Jun 2026 at about KRW 1,867

Treasury shares

—0.07—

Competitive Landscape

Competitors by Segment

BusinessCompetitorDescriptionLatest disclosed scale

Medical aesthetics platform

Healing Paper (Gangnam Unni)

Market leader in aesthetics information; Japan subsidiary (acquired Lukumo, 2020); Thai-language "UNNI"

FY2024 revenue KRW 53.0 bn, operating profit KRW 12.9 bn; Series C KRW 42.8 bn (Feb 2025) at about KRW 580–600 bn valuation

Medical aesthetics platform

Fastrain (Yeoshin Ticket)

Aesthetic-procedure ticketing platform

—

Telemedicine

Doctor Now

Largest telemedicine platform

1.45 million consultations in H1 2026; 8,600 partner institutions; over KRW 60 bn raised cumulatively

Booking / registration

B-Bros (Ddocdoc)

Clinic booking/registration; UBcare is largest shareholder (37.8% in 2022)

7 million members (2022); cumulative funding KRW 38.8 bn through Series D

Telemedicine

Merakiplace (My Doctor / 나만의닥터)

Telemedicine app

FY2024 revenue about KRW 0.8 bn (secondary source)

Health platforms

Kakao Healthcare

Big-tech health data and platforms

—

Hospital apps / insurance claims

Lemon Healthcare

Hospital apps, paperless insurance claims

—

EMR / pharmacy software

UBcare (GC group)

EMR leader; pharmacy software; owner of B-Bros stake

—

Clinic CRM

Meta Labs (Meta S&C)

CRM for non-reimbursed specialty clinics (hair-loss, diet), listed

FY2025 revenue KRW 81.4 bn, operating loss KRW 7.1 bn (group, incl. distribution)

Healthcare recruiting / generic

Generic job portals and specialist platforms

——

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricCarelabs (FY2025)Babitalk standalone (FY2025)Healing Paper (FY2024)Meta Labs (FY2025)

Revenue (KRW Bn)

81.6936.8053.0081.40

Operating income (KRW Bn)

-2.887.3012.90-7.10

Operating margin (%)

-3.519.824.3-8.7

Revenue growth (%)

-1.8—

~20

112

Company Snapshot

$57.5M

Revenue

123

Employees

2012

Founded

SWOT Analysis

Strengths

  • Profitable core asset: Babitalk earned KRW 7.3 bn operating profit on KRW 36.8 bn revenue in FY2025 (19.8% margin) [S29].
  • Scale of user base: Babitalk passed 10 million cumulative downloads and first exceeded KRW 10 bn quarterly revenue in Q1 2026 [S17].
  • Long profitability record: Babitalk had 34 consecutive profitable quarters as of H1 2024 [S60].
  • Profitable niche software: EDB grew Q1 2026 revenue 24% to KRW 3.5 bn, with operating profit up 255% [S17].
  • Deleveraged parent: separate liabilities fell from KRW 65.8 bn (FY2024) to KRW 7.7 bn (FY2025) with short-term borrowings eliminated [S1][S12].
  • Committed controlling shareholder: Wonik Holdings has invested about KRW 77.7 bn and keeps buying shares (185,000 in Jun–Jul 2026; 200,000 planned from Sep 2026) [S6].

Weaknesses

  • Persistent operating losses: operating losses every year FY2022–FY2025, peaking at KRW 11.6 bn in FY2023 [S1][S5].
  • Shrinking revenue: consolidated revenue fell from KRW 93.9 bn (FY2021) to KRW 81.7 bn (FY2025) and 20.3% YoY in H1 2026 [S5][S7].
  • Goodoc value destruction: Goodoc's revenue fell from about KRW 12.1 bn to KRW 1.0 bn and its equity was KRW -8.4 bn in June 2026 despite KRW 20 bn of injections since 2023 [S7].
  • Low-quality FY2025 earnings: the KRW 19.5 bn net profit relied on a KRW 25.9 bn related-party property gain [S10][S6].
  • Declining parent services: parent revenue fell 17.6% in FY2025 and 36.2% YoY in Q1 2026 [S1][S12].
  • Accumulated deficit: about KRW 45 bn in early 2025 [S8].

Opportunities

  • Inbound aesthetics boom: foreign patients reached 2.01 million in 2025, with dermatology up 86.2% YoY [S50][S51].
  • Japan: Japanese patients numbered about 600,000 in 2025, and Babitalk now has both Japanese web and app services [S50][S17].
  • Telemedicine legal certainty from late 2026 could benefit established intermediaries, including Goodoc (25% MAU growth in Q1 2026) [S48][S17].
  • Integrated clinic offering after the Babitalk merger: combining platform ads with external performance marketing and CRM [S73].
  • Ageing-related services: Yobosarang (25,000 care workers, 1,500 institutions at acquisition) and planned senior-care facility [S25][S30].
  • Heal-O: a differentiated oncology vertical with AI features launched at low cost within the parent [S27].

Threats

  • Stronger rival in aesthetics: Gangnam Unni had KRW 53.0 bn revenue and KRW 12.9 bn operating profit in 2024 and raised KRW 42.8 bn in 2025 [S52][S53].
  • Telemedicine scale gap: Doctor Now handled 1.45 million consultations in H1 2026 [S54].
  • Platform regulation: new rules subject telemedicine intermediaries to advertising pre-review and broad conduct prohibitions [S49].
  • Delisting thresholds: KOSDAQ minimum market cap rises to KRW 30 bn in 2027 versus Carelabs' ~KRW 39 bn [S6][S5].
  • Capital allocation into real estate: a KRW 75.11 bn land commitment equal to 52.43% of then-total assets [S30].
  • Governance perception: press scrutiny of owner-family management and related-party dealings [S6][S7][S8].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Feb 2025 (context)KRW 59.6 bn property-sale balance received [S8]Funded debt repayment
15 May 2025Q1 2025: revenue KRW 23.1 bn (+3.1%), operating profit KRW 0.84 bn (+164%), net income KRW 25.5 bn [S15]Property gain booked
22 Jul 2025Yobosarang acquisition completed [S25]Entry into care-worker matching
Aug 2025H1 2025: revenue KRW 45.6 bn (+9.2%), operating profit KRW 3.4 bn, net income KRW 24.7 bn [S14]High-water mark of recent results
25 Aug 2025Babitalk launches Japanese web service [S28]First international step
27 Aug 2025Heal-O oncology platform launched [S26]New vertical
17 Sep 2025Godeok-Gangil land 1-2 acquired for KRW 75.11 bn [S30]Large capital commitment to senior care
23 Oct 2025Godeok-Gangil land 1-1 acquisition decision [S31]Further commitment
Nov 2025Additional KRW 10.0 bn injected into Goodoc; new Goodoc CEO [S7]Ongoing subsidiary drain
2 Dec 2025Telemedicine legalisation passes National Assembly [S47][S48]Structural change for Goodoc; effective about one year after promulgation
2025 (date n/d)Medijob recognised with a Minister of Employment and Labor award [Venturesquare tag page]Recruiting franchise
10 Feb 2026FY2025 preliminary results; net profit turnaround on asset-sale gain [S9]Headline profit is one-off
Feb 2026Goodoc offers holiday telemedicine to first-visit and repeat patients [Goodoc news via CB Insights snippet]Usage driver
19 Mar 2026Disclosure of 30%+ change in P&L structure [S64]Formalises FY2025 swing
27 Mar 2026AGM: CEO re-elected; new business purposes; senior-care strategy [S22][S23]Strategic direction
22 Apr 2026Heal-O major upgrade [S27]Product iteration
24 Apr 2026Government reports 2.01 million foreign patients in 2025 [S50][S51]Demand tailwind for Babitalk
15–18 May 2026Q1 2026: revenue KRW 20.5 bn (-11%), operating profit KRW 0.67 bn (-20%); Babitalk quarterly revenue tops KRW 10 bn; EDB revenue KRW 3.5 bn [S16][S17]Core engine strengthening; group shrinking
29 May 2026Yobosarang–Medijob integrated job posting [Venturesquare tag page]Product synergy
8 Jun 2026CEO buys 53,472 shares [S6]Signalling
22 Jun–6 Jul 2026Wonik Holdings buys 185,000 shares at about KRW 1,950 [S6]Controlling-shareholder support
1 Jul 2026CSO and Goodoc CTO appointed [S24]Strategy and technology upgrade
Jul 2026KOSDAQ market-cap delisting threshold raised to KRW 20 bn (KRW 30 bn from 2027) [S6]Relevant given KRW ~39 bn market cap
Aug 2026H1 2026: revenue KRW 37.9 bn (-20.3%), operating loss KRW 0.05 bn; Goodoc H1 net loss KRW 2.8 bn and equity of KRW -8.4 bn [S6][S7]Deterioration
1–2 Sep 2026Critical governance coverage by Bizwatch [S6][S7]Reputational
from 7 Sep 2026Wonik Holdings' planned purchase of 200,000 shares (1.03%) [S6]Stake towards 33.76%
2 Oct 2026Large-shareholding report and insider report filed [S5]–
15 Oct 2026Babitalk merger decision; EGM called for 26 Nov 2026 to amend articles [S18][S20]Structural simplification
12 Nov 2026 (expected)Q3 2026 results [S57]Next datapoint

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: Consolidated revenue fell from KRW 93,900 Mn in FY2021 to KRW 81,690 Mn in FY2025.
Carelabs Co., Ltd. — Revenue by Segment
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Consolidated revenue93,90087,61081,83083,19081,690
Carelabs parent revenue, separate——37,24041,03033,820
Babitalk revenue————36,800
Goodoc revenue12,1007,8004,5001,0001,000
EDB, other and eliminations residual————10,070

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Carelabs IR – Financial Information (FY2023–FY2025, consolidated and separate) (carelabs.co.kr)
  2. S2Carelabs – Company History (carelabs.co.kr)
  3. S3Carelabs – Business Divisions (carelabs.co.kr)
  4. S4Carelabs – Subsidiaries (carelabs.co.kr)
  5. S5Butler.works – Carelabs (263700) profile, annual results, segment mix, recent filings (butler.works)
  6. S6Bizwatch, Governance Watch – Carelabs Part 1 (1 Sep 2026) (news.bizwatch.co.kr)
  7. S7Bizwatch, Governance Watch – Carelabs Part 2, Goodoc (2 Sep 2026) (news.bizwatch.co.kr)
  8. S8Bizwatch via Daum – Wonik affiliate Carelabs and Lee Min-kyung (3 Feb 2025) (v.daum.net)
  9. S9DigitalToday via Nate – FY2025 preliminary results (10 Feb 2026) (news.nate.com)
  10. S10KRX KIND – Carelabs half-year report H1 2025 (kind.krx.co.kr)
  11. S11FnGuide – Carelabs main page (EPS, ROA) (comp.fnguide.com)
  12. S12FnGuide – Carelabs separate financial statements (comp.fnguide.com)
  13. S13Google Finance – 263700:KOSDAQ quarterly data and statistics (google.com)
  14. S14Thinkpool – Carelabs results history (m.thinkpool.com)
  15. S15Thinkpool – Q1 2025 results flash (m.thinkpool.com)
  16. S16Edaily – Q1 2026 results (18 May 2026) (edaily.co.kr)
  17. S17Venturesquare – Q1 2026: Babitalk tops KRW 10 bn (18 May 2026) (venturesquare.net)
  18. S18Kormedi – Carelabs to absorb Babitalk (15 Oct 2026) (kormedi.com)
  19. S19Chickstock – Merger decision filing summary (15 Oct 2026) (chickstockfi.com)
  20. S20Chickstock – EGM convocation summary (15 Oct 2026) (chickstockfi.com)
  21. S21Financial News – Babitalk merger and medical tourism (15 Oct 2026) (fnnews.com)
  22. S22Medigate News – AGM and senior-care entry (31 Mar 2026) (medigatenews.com)
  23. S23DigitalToday via Nate – 14th AGM results (27 Mar 2026) (m.news.nate.com)
  24. S24Edaily English – CSO and Goodoc CTO appointments (Jul 2026) (en.edaily.co.kr)
  25. S25Medigate News – Yobosarang acquisition (22 Jul 2025) (medigatenews.com)
  26. S26Unicorn Factory – Heal-O launch (27 Aug 2025) (unicornfactory.co.kr)
  27. S27Medigate News – Heal-O upgrade (23 Apr 2026) (medigatenews.com)
  28. S28Byline Network – Babitalk Japan web launch (25 Aug 2025) (byline.network)
  29. S29Wanted – Babitalk job posting citing FY2025 revenue and operating profit (wanted.co.kr)
  30. S30DigitalToday – KRW 75.11 bn Godeok land acquisition (17 Sep 2025) (digitaltoday.co.kr)
  31. S31Saramin – Carelabs company timeline (2025 land acquisitions) (saramin.co.kr)
  32. S32Edaily – KRW 95 bn property sale to Hwain Yutong (edaily.co.kr)
  33. S33Energy Economy (EKN) – Failed property sale (18 Mar 2024) (m.ekn.kr)
  34. S34Edaily – KRW 36.99 bn Yeoksam-dong property acquisition (edaily.co.kr)
  35. S35iNews24 – Carelabs joins Wonik Group (Jan 2023) (inews24.com)
  36. S36Edaily – CityLabs sells Carelabs stake for KRW 64.7 bn (edaily.co.kr)
  37. S37Dealsite – Daily Blockchain acquires Carelabs (1 Apr 2019) (dealsite.co.kr)
  38. S38Etoday – Failed sale; GC and executives sell shares (3 Jul 2020) (etoday.co.kr)
  39. S39Edaily – Carelabs sale collapses (2020) (edaily.co.kr)
  40. S40Carelabs IR press release – FY2018 results (via Alphasquare) (file.alphasquare.co.kr)
  41. S41Edaily – FY2019 results (edaily.co.kr)
  42. S42Asia Economy – FY2020 results (core.asiae.co.kr)
  43. S43Edaily – FY2021 results (edaily.co.kr)
  44. S44Asia Economy – Goodoc KRW 21 bn Series A (9 May 2022) (core.asiae.co.kr)
  45. S45Unicorn Factory Datalab – Goodoc profile (Samsung Life, Kakao partnership, revenue history) (unicornfactory.co.kr)
  46. S46Goodoc website (corporate footer, ISMS certification) (goodoc.co.kr)
  47. S47Ministry of Health and Welfare – Telemedicine law passes (2 Dec 2025) (mohw.go.kr)
  48. S48Korea.kr Policy News – Telemedicine institutionalisation details (3 Dec 2025) (korea.kr)
  49. S49ETNews – Platform industry concerns on telemedicine bill (20 Nov 2025) (etnews.com)
  50. S50Herald Economy – 2025 foreign patients exceed 2 million (24 Apr 2026) (heraldk.com)
  51. S51KDI Economic Information Center – MoHW foreign patient statistics summary (eiec.kdi.re.kr)
  52. S52Innoforest – 2026 analysis of aesthetics platforms (Gangnam Unni, Babitalk, Yeoshin Ticket) (innoforest.co.kr)
  53. S53Dealsite – Healing Paper KRW 42.8 bn Series C (16 Feb 2025) (dealsite.co.kr)
  54. S54Hankyung – Doctor Now H1 2026 consultations (9 Jul 2026) (hankyung.com)
  55. S55Dealsite – GC Holdings and B-Bros (Ddocdoc) (29 Nov 2022) (dealsite.co.kr)
  56. S56Asia Economy – Meta Labs FY2025 results (27 Feb 2026) (core.asiae.co.kr)
  57. S57Investing.com – Carelabs Co Ltd (263700) (ca.investing.com)
  58. S58StockHub – Carelabs (263700) (stockhub.kr)
  59. S59FinancialFilings – Carelabs investor relations and filings index (financialfilings.com)
  60. S60Unicorn Factory – Babitalk H1 2024 results (16 Aug 2024) (unicornfactory.co.kr)
  61. S61NextUnicorn – Babitalk H1 2021 results (nextunicorn.kr)
  62. S62Hanyang Securities – Carelabs report (Jun 2020) (file.alphasquare.co.kr)
  63. S63Korea Investment & Securities – Carelabs report (Jun 2019) (file.alphasquare.co.kr)
  64. S64GoInsider – Carelabs filings and consolidated summary (goinsider.kr)
  65. S66THE VC – Carelabs profile (thevc.kr)
  66. S67Edaily – 2020 EGM for Goodoc spin-off (edaily.co.kr)
  67. S68Medical Times – Goodoc and GC Wellbeing partnership (Nov 2018) (medicaltimes.com)
  68. S69Asia Economy – Goodoc registration and booking usage (Nov 2021) (core.asiae.co.kr)
  69. S70Asia Economy – Goodoc selected for Korea Innovation Fair 2021 (core.asiae.co.kr)
  70. S71Stockopedia – Carelabs news briefs (CBs, LifeSemantics, real estate) (www-proxy.stockopedia.com)
  71. S72Asia Economy – 2020 broker forecast (asiae.co.kr)
  72. S73Unicorn Factory – Carelabs to absorb Babitalk (15 Oct 2026) (unicornfactory.co.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.